12:19 PM EST, 11/06/2025 (MT Newswires) -- Travere Therapeutics ( TVTX ) reported mixed results Thursday from a late-stage clinical trial of its drug Filspari for a rare kidney disease.

While the trial met a secondary goal of partial remission of proteinuria with statistical significance at 36 weeks, it failed to meet the primary endpoint measuring kidney function decline over 108 weeks using the eGFR slope, a marker of estimated glomerular filtration rate, the company said.

Results showed Filspari helped significantly more patients reach a key treatment goal compared with irbesartan, the company said.

The disease, focal segmental glomerulosclerosis, affects the kidney's filtering units. The goal was to reduce protein levels in urine below 0.7 grams per gram, a threshold linked to a lower risk of kidney failure, the company said.

Earlier research had identified that protein-to-creatinine ratio target as clinically meaningful for people with the disease, the company said.

Price: 33.79, Change: +0.07, Percent Change: +0.21